Back to Authors

Foran, James M.

https://orcid.org/0000-0003-1673-1708

A5035051206 | I4210146710

Mayo Clinic in Florida

Citations 327

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9070-9073

10.1182/blood-2022-166715

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6940-6941

10.1182/blood-2022-163518

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 583-585

10.1182/blood-2022-157949

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2016-2019

10.1182/blood-2022-166850

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2887-2890

10.1182/blood-2022-162367

U2AF1 Mutant Clonal Hematopoiesis Is Infrequent, Context Dependent, and Commonly Co-Occurs with BCOR Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11408-11409

10.1182/blood-2022-166794